HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Development of an ErbB4 monoclonal antibody that blocks neuregulin-1-induced ErbB4 activation in cancer cells.

Abstract
The use of monoclonal antibodies (mAbs) for cancer therapy is one of the most important strategies for current cancer treatment. The epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, which regulates cancer cell proliferation, survival, and migration, is a major molecular target for antibody-based therapy. ErbB4/HER4, which contains a ligand-binding extracellular region, is activated by several ligands, including neuregulins (NRGs), heparin-binding EGF-like growth factor, betacellulin and epiregulin. Although there are clinically approved antibodies for ErbB1 and ErbB2, there are no available therapeutic mAbs for ErbB4, and it is not known whether ErbB4 is a useful target for antibody-based cancer therapy. In this study, we developed an anti-ErbB4 mAb (clone P6-1) that suppresses NRG-dependent activation of ErbB4 and examined its effect on breast cancer cell proliferation in the extracellular matrix.
AuthorsShogo Okazaki, Fumi Nakatani, Kazue Masuko, Kenji Tsuchihashi, Shiho Ueda, Takashi Masuko, Hideyuki Saya, Osamu Nagano
JournalBiochemical and biophysical research communications (Biochem Biophys Res Commun) Vol. 470 Issue 1 Pg. 239-244 (Jan 29 2016) ISSN: 1090-2104 [Electronic] United States
PMID26780728 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.
Chemical References
  • Antibodies, Monoclonal
  • NRG1 protein, human
  • Neuregulin-1
  • ERBB4 protein, human
  • Receptor, ErbB-4
Topics
  • Antibodies, Monoclonal (genetics, immunology, therapeutic use)
  • Apoptosis (drug effects)
  • Cell Proliferation (drug effects)
  • Cell Survival (drug effects)
  • Cloning, Molecular (methods)
  • Drug Design
  • Humans
  • MCF-7 Cells
  • Molecular Targeted Therapy (methods)
  • Neoplasms, Experimental (drug therapy, immunology, pathology)
  • Neuregulin-1 (immunology)
  • Receptor, ErbB-4 (immunology)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: